Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Harvoni was produced by Bristol-Myers Squibb.

J&J signs $1bn deal with Achillion for hepatitis C therapies

J&J signs $1bn deal with Achillion for hepatitis C therapies Gilead is already selling a dual drug regimen for HCV called Harvoni (sofosbuvir/ledipasvir) that is growing quickly in the marketplace, while AbbVie is also seeing sales of its combination therapy ... weeks currently required with Harvoni and

Harvoni sales rocket in first quarter

Harvoni sales rocket in first quarter Sovaldi was approved across US and European markets in January last year while Harvoni was launched in the fourth quarter. ... In both of these markets, 90, 000 patients started treatment on Sovaldi or Harvoni during the first quarter, Gilead said in a

Pharma deals in February 2015

Pharma deals in February 2015 exclusive agreement with Gilead Sciences to distribute Sovaldi and Harvoni in India, time has been found to ink the acquisition of certain female reproductive healthcare business units from Mumbai-based Famy

BMS' Opdivo backed as melanoma therapy in EU

BMS' Opdivo backed as melanoma therapy in EU Safety issue with new HCV drugs. The CHMP also said it had confirmed a risk of severe bradycardia or heart block when Gilead's hepatitis C drug Harvoni (sofosbuvir with ledipasvir) -

Merck's breakthrough HCV drug aces trial

Merck's breakthrough HCV drug aces trial Despite the lead for rival oral HCV therapies such as Gilead's Sovaldi (sofosbuvir) and Harvoni (sofosbuvir and ledipasvir) and AbbVie's Viekira Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir), consensus analyst

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics